Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers

Yumiko Akamine, Masatomo Miura, Hisakazu Komori, Shun Saito, Hiroyuki Kusuhara, Ikumi Tamai, Ichiro Ieiri, Tsukasa Uno, Norio Yasui-Furukori

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. Methods: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 μM (R)- and (S)-fexofenadine in the presence or absence of 10 % apple juice. Results: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 %, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P∈<∈0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 %, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. Conclusions: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.

Original languageEnglish
Pages (from-to)1087-1095
Number of pages9
JournalEuropean Journal of Clinical Pharmacology
Volume70
Issue number9
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

fexofenadine
Malus
Pharmacokinetics
Eating
Anions
Peptides
Oocytes
Complementary RNA
Water

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Akamine, Y., Miura, M., Komori, H., Saito, S., Kusuhara, H., Tamai, I., ... Yasui-Furukori, N. (2014). Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. European Journal of Clinical Pharmacology, 70(9), 1087-1095. https://doi.org/10.1007/s00228-014-1705-y

Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. / Akamine, Yumiko; Miura, Masatomo; Komori, Hisakazu; Saito, Shun; Kusuhara, Hiroyuki; Tamai, Ikumi; Ieiri, Ichiro; Uno, Tsukasa; Yasui-Furukori, Norio.

In: European Journal of Clinical Pharmacology, Vol. 70, No. 9, 01.01.2014, p. 1087-1095.

Research output: Contribution to journalArticle

Akamine, Y, Miura, M, Komori, H, Saito, S, Kusuhara, H, Tamai, I, Ieiri, I, Uno, T & Yasui-Furukori, N 2014, 'Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers', European Journal of Clinical Pharmacology, vol. 70, no. 9, pp. 1087-1095. https://doi.org/10.1007/s00228-014-1705-y
Akamine, Yumiko ; Miura, Masatomo ; Komori, Hisakazu ; Saito, Shun ; Kusuhara, Hiroyuki ; Tamai, Ikumi ; Ieiri, Ichiro ; Uno, Tsukasa ; Yasui-Furukori, Norio. / Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. In: European Journal of Clinical Pharmacology. 2014 ; Vol. 70, No. 9. pp. 1087-1095.
@article{6f7d68d68f974ce2858f70126fcc8f2d,
title = "Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers",
abstract = "Purpose: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. Methods: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 μM (R)- and (S)-fexofenadine in the presence or absence of 10 {\%} apple juice. Results: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 {\%}, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P∈<∈0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 {\%}, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. Conclusions: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.",
author = "Yumiko Akamine and Masatomo Miura and Hisakazu Komori and Shun Saito and Hiroyuki Kusuhara and Ikumi Tamai and Ichiro Ieiri and Tsukasa Uno and Norio Yasui-Furukori",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00228-014-1705-y",
language = "English",
volume = "70",
pages = "1087--1095",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers

AU - Akamine, Yumiko

AU - Miura, Masatomo

AU - Komori, Hisakazu

AU - Saito, Shun

AU - Kusuhara, Hiroyuki

AU - Tamai, Ikumi

AU - Ieiri, Ichiro

AU - Uno, Tsukasa

AU - Yasui-Furukori, Norio

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. Methods: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 μM (R)- and (S)-fexofenadine in the presence or absence of 10 % apple juice. Results: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 %, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P∈<∈0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 %, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. Conclusions: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.

AB - Purpose: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. Methods: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 μM (R)- and (S)-fexofenadine in the presence or absence of 10 % apple juice. Results: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 %, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P∈<∈0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 %, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. Conclusions: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.

UR - http://www.scopus.com/inward/record.url?scp=84906262772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906262772&partnerID=8YFLogxK

U2 - 10.1007/s00228-014-1705-y

DO - 10.1007/s00228-014-1705-y

M3 - Article

C2 - 24903351

AN - SCOPUS:84906262772

VL - 70

SP - 1087

EP - 1095

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 9

ER -